Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab

Akmal S Hassan; Ursula Kaelin; Lasse Roger Braathen; Nikhil Yawalkar

doi:10.1016/j.jaad.2006.08.025

Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab

J Am Acad Dermatol. 2007 Feb;56(2):217-21. doi: 10.1016/j.jaad.2006.08.025. Epub 2006 Nov 16.

Authors

Akmal S Hassan¹, Ursula Kaelin, Lasse Roger Braathen, Nikhil Yawalkar

Affiliation

¹ Department of Dermatology, University of Bern, Inselspital, Switzerland.

PMID: 17113187
DOI: 10.1016/j.jaad.2006.08.025

Abstract

Treatment of widespread moderate to severe atopic eczema remains a challenge. The therapeutic efficacy and modifications of the immune response during treatment of atopic eczema with efalizumab are so far unknown. We hereby report the clinical findings and characterize the inflammatory infiltrate during treatment of severe recalcitrant atopic eczema with efalizumab.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
CD11 Antigens / immunology
Dermatitis, Atopic / drug therapy*
Dermatitis, Atopic / immunology
Dermatitis, Atopic / metabolism
Dermatitis, Atopic / pathology
Humans
Immunohistochemistry
Macrophages / immunology
Male
Skin / immunology
Skin / pathology

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
CD11 Antigens
efalizumab